GHR’s Health initiative partners with organizations using innovative trials to pursue the prevention of Alzheimer’s disease. One such trial is the Alzheimer’s Prevention Initiative (API) Generation Study which recently began enrollment in high-risk older adults to validate the use of genetic screening and identify an effective approach to prevent the disease.
Led by Dr. Eric Reiman and Dr. Pierre Tariot of Banner Alzheimer’s Institute (BAI), this pioneering multi-site prevention study is working to determine whether two investigational anti-amyloid compounds—an active immunotherapy and an oral medication—can prevent or delay the emergence of Alzheimer’s symptoms in people at a high genetic risk of developing the disease. The study will involve more than 1,300 cognitively healthy adults, age 60 to 75, who have inherited a copy of the e4 type of the apolipoprotein (APOE) gene from each parent. Roughly one in four people carry a single copy of the gene, which is strongly linked to late-onset Alzheimer’s.
The Generation Study is part of the API, an international collaborative led by BAI to accelerate the evaluation of promising treatments. The study is sponsored by Swiss pharmaceutical company Novartis and Thousand Oaks, Calif.-based biotechnology company Amgen in collaboration with BAI, with funding from the National Institute on Aging—part of the National Institutes of Health—as well as GHR, Alzheimer’s Association, Fidelity Biosciences Research Institute and Banner Alzheimer’s Foundation.
To learn more about how GHR is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on the prevention of Alzheimer’s disease, contact us.
Led by Dr. Eric Reiman and Dr. Pierre Tariot of Banner Alzheimer’s Institute (BAI), this pioneering multi-site prevention study is working to determine whether two investigational anti-amyloid compounds—an active immunotherapy and an oral medication—can prevent or delay the emergence of Alzheimer’s symptoms in people at a high genetic risk of developing the disease. The study will involve more than 1,300 cognitively healthy adults, age 60 to 75, who have inherited a copy of the e4 type of the apolipoprotein (APOE) gene from each parent. Roughly one in four people carry a single copy of the gene, which is strongly linked to late-onset Alzheimer’s.
The Generation Study is part of the API, an international collaborative led by BAI to accelerate the evaluation of promising treatments. The study is sponsored by Swiss pharmaceutical company Novartis and Thousand Oaks, Calif.-based biotechnology company Amgen in collaboration with BAI, with funding from the National Institute on Aging—part of the National Institutes of Health—as well as GHR, Alzheimer’s Association, Fidelity Biosciences Research Institute and Banner Alzheimer’s Foundation.
To learn more about how GHR is joining forces with industry, other philanthropic partners and the United States National Institutes of Health on the prevention of Alzheimer’s disease, contact us.
RSS Feed
